Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Teva acquires pain company Labrys for $825m

This article was originally published in Scrip

Executive Summary

Teva has agreed to buy Labrys, a Californian manufacturer of pain products with a Phase IIb migraine product. The Israeli company said the acquisition adds an important dimension to its growing pain franchise.

You may also be interested in...



Finance Watch: Two New VC Funds Target Early Stage And Beyond

Private Company Edition: venBio’s new fund plus Ysios Capital’s recent €216m ($260m) fund adds up to $810m in fresh venture capital for life science companies. Also, Nikang and Esco attracted $200m each in VC investment, Pulmocide closed a $92m series C round and Stablix launched with $63m. 

Teva's CGRP Inhibitor Fails In Chronic Cluster Headaches, Continues In Episodic

Unlike the migraine space, there is only one competitor for Teva's CGRP inhibitor in cluster headaches, but that opportunity narrowed with fremanezumab's failure in chronic cluster headaches, though a trial in episodic cluster headaches is ongoing.

venBio's $315m Pharma-Backed Fund Seeks Broad Range Of Investments

VenBio has $315m in new cash to invest in a broad array of therapeutics developers now that it has closed its second venture capital fund, which raised $65m more than the VC firm originally intended and reflects big pharma's increasing commitment to backing early-stage life science companies.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC025480

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel